TY - JOUR
T1 - Pharmacologic prophylaxis regimens for acute graft-versus-host disease
T2 - Past, present and future
AU - Ram, Ron
AU - Storb, Rainer
N1 - Funding Information:
The authors are grateful for research funding from the National Institutes of Health, Bethesda, MD, grants CA 78902, CA 18029 and CA 15704.
PY - 2013/8
Y1 - 2013/8
N2 - Acute graft-versus-host disease (GVHD) has compromised and continues to compromise the benefits associated with allogeneic hematopoietic cell transplant to cure malignant and non-malignant diseases. Pharmacologic interventions to prevent GVHD have emerged as a major objective of research in the immunology and transplant fields. A better understanding of the pathobiology behind the GVHD process has led the way to novel approaches and medications. Here we review the present arsenal of medications used to prevent GVHD, focusing on past experience and the current evidence, and discuss future potential targets.
AB - Acute graft-versus-host disease (GVHD) has compromised and continues to compromise the benefits associated with allogeneic hematopoietic cell transplant to cure malignant and non-malignant diseases. Pharmacologic interventions to prevent GVHD have emerged as a major objective of research in the immunology and transplant fields. A better understanding of the pathobiology behind the GVHD process has led the way to novel approaches and medications. Here we review the present arsenal of medications used to prevent GVHD, focusing on past experience and the current evidence, and discuss future potential targets.
KW - Allogeneic transplant
KW - GVHD
KW - Prophylaxis
UR - http://www.scopus.com/inward/record.url?scp=84880277026&partnerID=8YFLogxK
U2 - 10.3109/10428194.2012.762978
DO - 10.3109/10428194.2012.762978
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 23278640
AN - SCOPUS:84880277026
SN - 1042-8194
VL - 54
SP - 1591
EP - 1601
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 8
ER -
